1. Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones. 2013; 45:141–147. PMID:
23770795.
2. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005; 2:29. PMID:
16232315.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21:1414–1431. PMID:
9727886.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16:434–444. PMID:
8432214.
5. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991; 151:1141–1147. PMID:
2043016.
6. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001; 44:2107–2114. PMID:
11793012.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414:813–820. PMID:
11742414.
8. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005; 54:1–7. PMID:
15616004.
9. Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab. 1999; 1:215–220. PMID:
11228756.
10. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care. 1992; 15:792–805. PMID:
1600838.
11. Kumar S, Narwal S, Kumar V, Prakash O. α-Glucosidase inhibitors from plants: a natural approach to treat diabetes. Pharmacogn Rev. 2011; 5:19–29. PMID:
22096315.
12. Mai TT, Thu NN, Tien PG, Van Chuyen N. Alpha-glucosidase inhibitory and antioxidant activities of Vietnamese edible plants and their relationships with polyphenol contents. J Nutr Sci Vitaminol (Tokyo). 2007; 53:267–276. PMID:
17874833.
13. Pei R, Yu M, Bruno R, Bolling BW. Phenolic and tocopherol content of autumn olive (Elaeagnus umbellate) berries. J Funct Foods. 2015; 16:305–314.
14. Khattak KF. Free radical scavenging activity, phytochemical composition and nutrient analysis of Elaeagnus umbellata berry. J Med Plants Res. 2012; 6:5196–5203.
15. Fordham IM, Clevidence BA, Wiley ER, Zimmerman RH. Fruit of autumn olive: a rich source of lycopene. HortScience. 2001; 36:1136–1137.
16. Wang SY, Fordham IM. Differences in chemical composition and antioxidant capacity among different genotypes of autumn olive (Elaeagnus umbellate Thunb.). Food Technol Biotechnol. 2007; 45:402–409.
17. Meeprom A, Sompong W, Suwannaphet W, Yibchok-anun S, Adisakwattana S. Grape seed extract supplementation prevents high-fructose diet-induced insulin resistance in rats by improving insulin and adiponectin signalling pathways. Br J Nutr. 2011; 106:1173–1181. PMID:
21736810.
18. Watanabe J, Kawabata J, Kurihara H, Niki R. Isolation and identification of α-glucosidase inhibitors from tochu-cha (
Eucommia ulmoides). Biosci Biotechnol Biochem. 1997; 61:177–178. PMID:
9028049.
19. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993; 123:1939–1951. PMID:
8229312.
20. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997; 20:1087–1092. PMID:
9203442.
21. Heo SJ, Hwang JY, Choi JI, Han JS, Kim HJ, Jeon YJ. Diphlorethohydroxycarmalol isolated from
Ishige okamurae, a brown algae, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice. Eur J Pharmacol. 2009; 615:252–256. PMID:
19482018.
22. Karato M, Yamaguchi K, Takei S, Kino T, Yazawa K. Inhibitory effects of pasuchaca (
Geranium dielsiaum) extract on α-glucosidase in mouse. Biosci Biotechnol Biochem. 2006; 70:1482–1484. PMID:
16794329.
23. Miura T, Koide T, Ohichi R, Kako M, Usami M, Ishihara E, Yasuda N, Ishida H, Seino Y, Tanigawa K. Effect of acarbose (α-glucosidase inhibitor) on disaccharase activity in small intestine in KK-Ay and ddY mice. J Nutr Sci Vitaminol (Tokyo). 1998; 44:371–379. PMID:
9742458.
24. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003; 163:1306–1316. PMID:
12796066.
25. Bahadoran Z, Mirmiran P, Azizi F. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J Diabetes Metab Disord. 2013; 12:43. PMID:
23938049.
26. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007; 125:451–472. PMID:
17496368.
27. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994; 121:928–935. PMID:
7734015.
28. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999; 22:960–964. PMID:
10372249.
29. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care. 2000; 23:1162–1167. PMID:
10937515.
30. Breuer HW. Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes. Int J Clin Pharmacol Ther. 2003; 41:421–440. PMID:
14703948.
31. Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A. New insight into adiponectin role in obesity and obesity-related diseases. BioMed Res Int. 2014; 2014:658913. PMID:
25110685.
32. Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, Diamanti-Kandarakis E, Kaltsas G, Kalofoutis A. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008; 28:314–321. PMID:
18224429.
33. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant. 2005; 20:2601–2604. PMID:
16188894.
34. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010; 12:365–383. PMID:
20415685.
35. Monnier L, Colette C, Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 2006; 12(Suppl 1):42–46. PMID:
16627379.
36. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346:393–403. PMID:
11832527.
37. O'Keefe JH Jr, Miles JM, Harris WH, Moe RM, McCallister BD. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999; 74:171–180. PMID:
10069357.